Phase III randomized study of folfoxiri plus bevacizumab and atezolizumab versus folfoxiri plus bevacizumab as first-line treatment of unresectable pMMR and immunoscore IC-high metastatic colorectal cancer patients
Phase III randomized study of folfoxiri plus bevacizumab and atezolizumab versus folfoxiri plus bevacizumab as first-line treatment of unresectable pMMR and immunoscore IC-high metastatic colorectal cancer patients
Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
AtezoTRIBE 2
Codice EudraCT
2023-506632-32-00
Sponsor/Promotore
GONO Gruppo Oncologico Nord Ovest
Tipologia
Sperimentale
Fase
III
Unità Operativa
UOS Sperimentazioni cliniche fasi precoci
Principal Investigator